These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

373 related items for PubMed ID: 32385738

  • 1. Ozanimod: First Approval.
    Lamb YN.
    Drugs; 2020 Jun; 80(8):841-848. PubMed ID: 32385738
    [Abstract] [Full Text] [Related]

  • 2. An Overview of the Efficacy and Safety of Ozanimod for the Treatment of Relapsing Multiple Sclerosis.
    Fronza M, Lorefice L, Frau J, Cocco E.
    Drug Des Devel Ther; 2021 Jun; 15():1993-2004. PubMed ID: 34007159
    [Abstract] [Full Text] [Related]

  • 3. Ozanimod: A Review in Relapsing Forms of Multiple Sclerosis.
    Nie T, Syed YY.
    CNS Drugs; 2024 Nov; 38(11):931-941. PubMed ID: 39368032
    [Abstract] [Full Text] [Related]

  • 4. Ozanimod (Zeposia) for multiple sclerosis.
    Med Lett Drugs Ther; 2020 Aug 24; 62(1605):132-134. PubMed ID: 32970043
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.
    Cohen JA, Comi G, Arnold DL, Bar-Or A, Selmaj KW, Steinman L, Havrdová EK, Cree BA, Montalbán X, Hartung HP, Huang V, Frohna P, Skolnick BE, Kappos L, RADIANCE Trial Investigators.
    Mult Scler; 2019 Aug 24; 25(9):1255-1262. PubMed ID: 30043658
    [Abstract] [Full Text] [Related]

  • 6. Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS.
    Harris S, Tran JQ, Southworth H, Spencer CM, Cree BAC, Zamvil SS.
    Neurol Neuroimmunol Neuroinflamm; 2020 Sep 24; 7(5):. PubMed ID: 32737072
    [Abstract] [Full Text] [Related]

  • 7. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.
    Cohen JA, Comi G, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Huang V, Kappos L, RADIANCE Trial Investigators.
    Lancet Neurol; 2019 Nov 24; 18(11):1021-1033. PubMed ID: 31492652
    [Abstract] [Full Text] [Related]

  • 8. Ozanimod for the treatment of relapsing forms of multiple sclerosis.
    Kuczynski AM, Oh J.
    Neurodegener Dis Manag; 2021 Jun 24; 11(3):207-220. PubMed ID: 34011158
    [Abstract] [Full Text] [Related]

  • 9. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial.
    Cohen JA, Arnold DL, Comi G, Bar-Or A, Gujrathi S, Hartung JP, Cravets M, Olson A, Frohna PA, Selmaj KW, RADIANCE Study Group.
    Lancet Neurol; 2016 Apr 24; 15(4):373-81. PubMed ID: 26879276
    [Abstract] [Full Text] [Related]

  • 10. Deconstructing the Pharmacological Contribution of Sphingosine-1 Phosphate Receptors to Mouse Models of Multiple Sclerosis Using the Species Selectivity of Ozanimod, a Dual Modulator of Human Sphingosine 1-Phosphate Receptor Subtypes 1 and 5.
    Selkirk JV, Dines KC, Yan YG, Ching N, Dalvie D, Biswas S, Bortolato A, Schkeryantz JM, Lopez C, Ruiz I, Hargreaves R.
    J Pharmacol Exp Ther; 2021 Dec 24; 379(3):386-399. PubMed ID: 34535564
    [Abstract] [Full Text] [Related]

  • 11. Ozanimod for the treatment of relapsing remitting multiple sclerosis.
    Rasche L, Paul F.
    Expert Opin Pharmacother; 2018 Dec 24; 19(18):2073-2086. PubMed ID: 30407868
    [Abstract] [Full Text] [Related]

  • 12. Absorption, Metabolism, and Excretion, In Vitro Pharmacology, and Clinical Pharmacokinetics of Ozanimod, a Novel Sphingosine 1-Phosphate Receptor Modulator.
    Surapaneni S, Yerramilli U, Bai A, Dalvie D, Brooks J, Wang X, Selkirk JV, Yan YG, Zhang P, Hargreaves R, Kumar G, Palmisano M, Tran JQ.
    Drug Metab Dispos; 2021 May 24; 49(5):405-419. PubMed ID: 33674268
    [Abstract] [Full Text] [Related]

  • 13. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.
    Comi G, Kappos L, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Ding N, Cohen JA, SUNBEAM Study Investigators.
    Lancet Neurol; 2019 Nov 24; 18(11):1009-1020. PubMed ID: 31492651
    [Abstract] [Full Text] [Related]

  • 14. Concentration-QTc Modeling of Ozanimod's Major Active Metabolites in Adult Healthy Subjects.
    Briggs E, Chapel S, Zhang P, Palmisano M, Tran JQ.
    CPT Pharmacometrics Syst Pharmacol; 2021 Feb 24; 10(2):119-126. PubMed ID: 33314790
    [Abstract] [Full Text] [Related]

  • 15. Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-Adjusted Indirect Comparison.
    Cohan S, Kumar J, Arndorfer S, Zhu X, Zivkovic M, Tencer T.
    CNS Drugs; 2021 Jul 24; 35(7):795-804. PubMed ID: 33847901
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics of S1P receptor modulators in the treatment of ulcerative colitis.
    Vieujean S, Peyrin-Biroulet L.
    Expert Opin Drug Metab Toxicol; 2024 Sep 24; 20(9):881-892. PubMed ID: 39252206
    [Abstract] [Full Text] [Related]

  • 17. Patients' Preferences for Sphingosine-1-Phosphate Receptor Modulators in Multiple Sclerosis Based on Clinical Management Considerations: A Choice Experiment.
    Keenan A, Whichello C, Le HH, Kern DM, Fernandez GS, Turner V, Das A, Quaife M, Ross AP.
    Patient; 2024 Nov 24; 17(6):685-696. PubMed ID: 38748388
    [Abstract] [Full Text] [Related]

  • 18. Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study.
    Feagan BG, Sandborn WJ, Danese S, Wolf DC, Liu WJ, Hua SY, Minton N, Olson A, D'Haens G.
    Lancet Gastroenterol Hepatol; 2020 Sep 24; 5(9):819-828. PubMed ID: 32553149
    [Abstract] [Full Text] [Related]

  • 19. In vitro assessment of the binding and functional responses of ozanimod and its plasma metabolites across human sphingosine 1-phosphate receptors.
    Selkirk JV, Yan YG, Ching N, Paget K, Hargreaves R.
    Eur J Pharmacol; 2023 Feb 15; 941():175442. PubMed ID: 36470447
    [Abstract] [Full Text] [Related]

  • 20. A critical review of ozanimod for the treatment of adults with moderately to severely active ulcerative colitis.
    Aoun R, Hanauer S.
    Expert Rev Gastroenterol Hepatol; 2022 May 15; 16(5):411-423. PubMed ID: 35400292
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.